Anngeen Technologies of Beijing raised more than $14 million in a Series B financing to support its gene sequencing services for clinical diagnosis. The company has set up at least 10 centers in partnership with hospitals to apply next-gen sequencing and bioinformatics to diagnose hereditary diseases in cardiovascular, kidney, blood and hereditary cancer conditions. It also provides individualized medication guidance and tumor molecular detection along with in vitro diagnostic kits. Anngeen wants to become the world's leading provider of genetic disease detection services. More details....
Share this with colleagues: